In its 2011 half-year update, Lonza shared some good news—strong operating performance in custom manufacturing, particularly for biologics, with 300 active projects in the pipeline, asset utilization approaching 80% and groundbreaking on a new manufacturing hu
All access premium subscription
This content requires a subscription to Nutrition Business Journal.
As an NBJ subscriber, you receive 10 issues a year and access to the exclusive “NBJ subscriber only” content on newhope.com (excludes three-month subscriptions), which includes PowerPoint presentations, select data charts and archived articles. Subscribers also receive a 10 percent discount on data charts, comprehensive market research reports and webinars.
Email [email protected] for more information about subscribing.